Isabelle Simoneau

Dijon, 21000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes.

Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: July 10, 2025

Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study.

Evolution of myocardial steatosis in high cardiovascular risk T2DM patients treated by GLP1 receptor agonists: LICAS study.

Journal: Diabetes research and clinical practice

Published: November 26, 2024

The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes.

The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes.

Journal: Metabolites

Published: August 13, 2024

Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes.

Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes.

Journal: Diabetes & metabolism

Published: March 27, 2024

No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.

No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes.

Journal: Diabetes & metabolism

Published: December 28, 2023

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes.

Journal: Cardiovascular diabetology

Published: February 23, 2023

Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring.

Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoring.

Journal: Acta diabetologica

Published: October 25, 2022

HDL functionality in type 1 diabetes: enhancement of cholesterol efflux capacity in relationship with decreased HDL carbamylation after improvement of glycemic control.

HDL functionality in type 1 diabetes: enhancement of cholesterol efflux capacity in relationship with decreased HDL carbamylation after improvement of glycemic control.

Journal: Cardiovascular diabetology

Published: June 03, 2022

Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities.

Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 18, 2021

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins.

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins.

Journal: Diabetes & metabolism

Published: August 18, 2021

Fewer Type A personality traits in type 2 diabetes patients with diabetic foot ulcer.

Fewer Type A personality traits in type 2 diabetes patients with diabetic foot ulcer.

Journal: Diabetes & metabolism

Published: December 24, 2020

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion.

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion.

Journal: Clinical pharmacology : advances and applications

Published: August 28, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026